No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Nkarta, Inc. (NKTX) stock was $2.31 as of Oct 6, 2026, 3:35 PM EDT, down 8.89% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +18.7% · 3-year avg +23.0%/yr · 5-year avg -37.3%/yr
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Biotechnology · South San Francisco, CA
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-0.40
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.54
vs Estimate
$-0.36
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NKTX | $164.91M | $2.31 | -8.89% | +18.68% | -37.28% | N/A | N/A |
| 2OPRX | $165.23M | $8.80 | +0.97% | -53.32% | -36.23% | +10.21% | vs NKTX |
| 3CUE | $166.66M | $22.94 | -5.82% | +11.33% | -42.42% | N/A | vs NKTX |
| 4QTRX | $162.75M | $3.46 | -9.32% | -37.20% | -39.63% | N/A | vs NKTX |
| 5CHRS | $161.45M | $1.04 | -6.70% | -31.58% | -41.38% | -26.92% | vs NKTX |
| 6MDWD | $168.66M | $13.13 | -2.81% | -21.32% | -9.04% | -12.86% | vs NKTX |
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 6 analysts
Average Price Target
$10.83
+370.0% upside
Low
$9.00
Current
$2.31
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.45 | $-0.40 | $-0.35 | 3 |
| Quarter ending Dec 2026 | $-0.44 | $-0.39 | $-0.32 | 3 |
| Quarter ending Mar 2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Quarter ending Jun 2027 | $-0.41 | $-0.41 | $-0.41 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.94 | $-1.67 | $-1.30 | 4 |
| FY 2027 | $-2.35 | $-1.52 | $-0.66 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.25M | $2.25M | $2.25M | 6 |
| FY 2027 | $6.50M | $6.50M | $6.50M | 6 |
